Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares Repurchased
Ratios

Corcept Therapeutics (CORT) Accumulated Depreciation & Amortization (2016 - 2023)

Historic Accumulated Depreciation & Amortization for Corcept Therapeutics (CORT) over the last 8 years, with Q2 2023 value amounting to $358000.0.

  • Corcept Therapeutics' Accumulated Depreciation & Amortization fell 1138.61% to $358000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $358000.0, marking a year-over-year decrease of 1138.61%. This contributed to the annual value of $3.7 million for FY2022, which is 2673.5% up from last year.
  • According to the latest figures from Q2 2023, Corcept Therapeutics' Accumulated Depreciation & Amortization is $358000.0, which was down 1138.61% from $172000.0 recorded in Q1 2023.
  • In the past 5 years, Corcept Therapeutics' Accumulated Depreciation & Amortization registered a high of $3.7 million during Q4 2022, and its lowest value of $172000.0 during Q1 2023.
  • Its 5-year average for Accumulated Depreciation & Amortization is $1.0 million, with a median of $447000.0 in 2020.
  • Per our database at Business Quant, Corcept Therapeutics' Accumulated Depreciation & Amortization skyrocketed by 58259.67% in 2021 and then crashed by 8365.03% in 2022.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Accumulated Depreciation & Amortization stood at $703000.0 in 2019, then surged by 163.58% to $1.9 million in 2020, then soared by 57.85% to $2.9 million in 2021, then rose by 26.74% to $3.7 million in 2022, then plummeted by 90.34% to $358000.0 in 2023.
  • Its Accumulated Depreciation & Amortization stands at $358000.0 for Q2 2023, versus $172000.0 for Q1 2023 and $3.7 million for Q4 2022.